CL2015003402A1 - Células madres adultas adiposas, humanas, pluripotentes: aislamiento, caracterización e implicaciones clinicas - Google Patents

Células madres adultas adiposas, humanas, pluripotentes: aislamiento, caracterización e implicaciones clinicas

Info

Publication number
CL2015003402A1
CL2015003402A1 CL2015003402A CL2015003402A CL2015003402A1 CL 2015003402 A1 CL2015003402 A1 CL 2015003402A1 CL 2015003402 A CL2015003402 A CL 2015003402A CL 2015003402 A CL2015003402 A CL 2015003402A CL 2015003402 A1 CL2015003402 A1 CL 2015003402A1
Authority
CL
Chile
Prior art keywords
characterization
fat
isolation
human
stem cells
Prior art date
Application number
CL2015003402A
Other languages
English (en)
Spanish (es)
Inventor
Gregorio Chazenbalk
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of CL2015003402A1 publication Critical patent/CL2015003402A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/73—Hydrolases (EC 3.)
    • C12N2501/734—Proteases (EC 3.4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/1382—Adipose-derived stem cells [ADSC], adipose stromal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1384—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from adipose-derived stem cells [ADSC], from adipose stromal stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
CL2015003402A 2013-05-22 2015-11-19 Células madres adultas adiposas, humanas, pluripotentes: aislamiento, caracterización e implicaciones clinicas CL2015003402A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361826417P 2013-05-22 2013-05-22

Publications (1)

Publication Number Publication Date
CL2015003402A1 true CL2015003402A1 (es) 2016-07-22

Family

ID=51934148

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015003402A CL2015003402A1 (es) 2013-05-22 2015-11-19 Células madres adultas adiposas, humanas, pluripotentes: aislamiento, caracterización e implicaciones clinicas

Country Status (5)

Country Link
US (4) US10131880B2 (enExample)
EP (2) EP3613846A1 (enExample)
JP (1) JP2016519939A (enExample)
CL (1) CL2015003402A1 (enExample)
WO (1) WO2014190150A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016519939A (ja) * 2013-05-22 2016-07-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ 多能性ヒト脂肪成体幹細胞：単離、キャラクタリゼーションおよび臨床的意味
JP6940101B2 (ja) * 2016-01-15 2021-09-22 国立大学法人富山大学 虚血性脳梗塞への多能性幹細胞の動員
US20190391147A1 (en) * 2016-04-07 2019-12-26 Rowan University Methods and kits for detecting myo/nog cells in human adipose tissue and methods of use thereof
SG11202011127WA (en) * 2018-05-09 2020-12-30 Life Science Institute Inc Therapeutic agent for spinal cord injury
US20230173065A1 (en) * 2020-05-15 2023-06-08 Seoul National University R&Db Foundation Composition for enhancing immune response by using activation function of dendritic cells of stromal vascular fractions isolated from adipose tissues
JP6864302B1 (ja) * 2020-07-03 2021-04-28 富士フイルム株式会社 滑膜由来間葉系幹細胞の製造方法および関節治療用細胞製剤の製造方法
WO2022104069A1 (en) 2020-11-13 2022-05-19 Advanced Therapeutic Lab, Inc. Therapeutic methods and compositions utilizing stromal vascular fraction derived from adipose tissue
CN117187174B (zh) * 2023-11-08 2024-02-06 广州正源生物技术有限公司 一种Muse细胞培养基以及一种脂肪Muse细胞的提取方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030082152A1 (en) 1999-03-10 2003-05-01 Hedrick Marc H. Adipose-derived stem cells and lattices
EP1903107A1 (en) 1999-09-24 2008-03-26 Cybios LLC Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
EP1261694B1 (en) 2000-02-26 2008-01-16 Artecel, Inc. Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof
DE10326750B4 (de) * 2003-06-13 2006-07-27 Gerlach, Jörg, Dr.med. Verfahren zur Herstellung einer Zellpräparation und derart hergestellte Zellpräparationen
AU2005322873B2 (en) 2004-12-30 2011-09-01 Primegen Biotech, Llc Adipose-derived stem cells for tissue regeneration and wound healing
KR100679642B1 (ko) * 2005-11-16 2007-02-06 주식회사 알앤엘바이오 인간 지방조직 유래 다분화능 줄기세포 및 이를 함유하는세포치료제
US20090304644A1 (en) * 2006-05-30 2009-12-10 Cytori Therapeutics, Inc. Systems and methods for manipulation of regenerative cells separated and concentrated from adipose tissue
US20090317367A1 (en) 2007-02-21 2009-12-24 Cedars-Sinai Medical Center Methods of producing preadipocytes and increasing the proliferation of adult adipose stem/progenitor cells
WO2010069008A1 (en) 2008-12-19 2010-06-24 Griffith University A germline competent cell derived from adult tissue
EP2446024A1 (en) * 2009-06-26 2012-05-02 Life&Light Limited Mesenchymal stem cells grown under hypoxic conditions: compositions, methods and uses therefor
US9399758B2 (en) * 2009-07-15 2016-07-26 Mari Dezawa SSEA3(+) pluripotent stem cell that can be isolated from body tissue
JP2014132830A (ja) * 2011-03-30 2014-07-24 Clio Inc 生体の臍帯又は脂肪組織から単離できる多能性幹細胞
US9550975B2 (en) 2009-07-15 2017-01-24 Mari Dezawa SSEA-3 pluripotent stem cell isolated from body tissue
US8501397B2 (en) * 2009-07-24 2013-08-06 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Enrichment of stem cells from adult tissues
US20120230966A1 (en) 2009-09-30 2012-09-13 Parcell Laboratories Llc Tissue transplant compositions and methods for use
JP5745533B2 (ja) 2009-12-18 2015-07-08 シャンハイ アイセル バイオテクノロジー カンパニー リミテッド 多能性幹細胞を製作するための材料と方法
KR20120002134A (ko) * 2010-06-30 2012-01-05 서울대학교산학협력단 지방 기질 세포의 역분화를 유도하는 방법
US20120028933A1 (en) * 2010-07-28 2012-02-02 Baust John M Cell Culture Media Supplement and Method of Molecular Stress Control
JP2016519939A (ja) * 2013-05-22 2016-07-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ 多能性ヒト脂肪成体幹細胞：単離、キャラクタリゼーションおよび臨床的意味

Also Published As

Publication number Publication date
US10131880B2 (en) 2018-11-20
US20240076623A1 (en) 2024-03-07
EP2999780B1 (en) 2019-10-09
EP2999780A4 (en) 2016-11-16
JP2016519939A (ja) 2016-07-11
US20210403872A1 (en) 2021-12-30
EP2999780A1 (en) 2016-03-30
US20190136193A1 (en) 2019-05-09
US11066647B2 (en) 2021-07-20
WO2014190150A1 (en) 2014-11-27
US20160108364A1 (en) 2016-04-21
US11913027B2 (en) 2024-02-27
EP3613846A1 (en) 2020-02-26

Similar Documents

Publication Publication Date Title
MX370018B (es) Metodos mejorados para la elaboracion de terapias celulares adoptivas.
BR112018068126A2 (pt) sistemas e métodos para a produção e liberação de pasta fluida gelada medicinal
TW201612312A (en) Meristematic plant cells and method of isolating them
UY34782A (es) Anticuerpos humanos para fel d1 y métodos para usarlos.
UY34577A (es) Método para estabilizar fibra de lignina y su posterior conversión en fibra de carbono
DK3325025T3 (da) Sammensætning og produkter omfattende aldrende celler til anvendelse i vævsregeneration
TWD170564S (zh) 杯子
BR112017012335A2 (pt) método, dispositivo e kit para a cultura em massa de células usando uma membrana de poli-imida porosa
MX342200B (es) Método de tratamiento de células madre mesenquimales y su uso en el tratamiento de enfermedades asociadas a estrés oxidativo.
EP3021791A4 (en) Tissue interface augmentation device for ligament/tendon reconstruction
EP2999780A4 (en) PLURIPOTENTIAL HUMAN ADULTS FAT TISSUE TREATMENT CELLS: INSULATION, CHARACTERIZATION, AND CLINICAL EFFECTS
BR112016030758B8 (pt) Uso de células estromais multipotentes derivadas de tecido adiposo mesenquimal
MX2016012823A (es) Inserto vaginal.
MX2015003701A (es) Composiciones para tratamiento.
CL2015001448A1 (es) Método para sincronización del tiempo de inseminación en cerdas jovenes
WO2014138426A3 (en) Methods and compositions for reducing body fat and adipocytes
BR112014019328A8 (pt) Perfil de fenótipo de células progenitoras retinais humanas
WO2014124307A3 (en) Targeted theranostics
BR112018008931A2 (pt) ?compostos para tratamento de distúrbios hipoproliferativos?
BR112016029558A2 (pt) terapia de células-tronco em patologias endometriais
IL274995B (en) Stem cells extracted from brown fat and their use
EP3189844A4 (en) Pluripotent stem cell for treating diabetic skin ulcer
UY34009A (es) ?uso de receptor de a2b adenosina para tratar la insuficiencia cardíaca y la arritmia en pacientes posinfarto de miocardio?.
BR112014021326A2 (pt) célula para a expressão de protéina, método para reduzir a atividade de amidação de peptídeo em uma determinada célula, uso de uma célula
IN2015DN00172A (enExample)